BDA-366
| CAS No. | 1821496-27-8 | Cat. No. | BCP25061 |
| Name | BDA-366 | ||
| Synonyms | BDA 366; BDA366; | ||
| Formula | C24H29N3O4 | M. Wt | 423.51 |
| Description | BDA-366 is a BCL2-BH4 antagonist. BDA-366 suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy. | ||
| Related Products | 1909226-00-1（BDA-366） 142645-19-0（BDA366） | ||
| Pathways | Apoptosis Pathway | ||
| Targets | Bcl2 | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.